NapaJen Pharma aims to be a game changer in the rising immuno-therapeutics era. NapaJen's Technology makes it possible to deliver low-dose cell-specific highly targeted therapies to "first responder" immune system cells (dendritic cells and macrophages).
Founded in 2004 by Mr. Hironori Ando (CEO) and Dr. Kazuo Sakurai (CSO), NapaJen is a privately held biotherapeutics company with HQ offices in the San Francisco Bay Area and R&D operations and scientific roots in Japan. Initially seed funded by Mitsui Global Investments (MGI), in February 2014 NapaJen became the recipient of a major series A investment from Innovation Network Corporation of Japan (INCJ) and MGI. In December 2016 NapaJen completed series B financing lead by INCJ in partnership with MGI, Nissay Capital Co., Ltd. and Mizuho Capital Co., Ltd,. In addition to seasoned executive support from its investors, NapaJen is guided by a group of distinguished international clinical, scientific and pharmaceutical Advisors and consultants on its path to commercial goals.